URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
UroGen Pharma Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$34.15−0.41 (-1.19%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
UroGen Pharma Ltd. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zusduri [Member] | $50.43M | $29.25M | $14.02M | $1.78M | $0 | $0 | $0 | $0 | – | – | – | – | 69.6% | – |
| Jelmyto [Member] | $22.03M | $21.71M | $23.82M | $25.70M | $24.22M | $20.25M | $24.57M | $25.20M | $21.85M | $18.78M | $23.53M | $20.85M | 30.4% | -9.0% |
By region
From the segment and revenue-disaggregation notes of UroGen Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.